ABSTRACT
Antibiotic resistance is an urgent public health threat: an estimated 2 out of every 5 infection deaths are associated with antibiotic resistant bacteria. Current actions to reduce this threat include requiring prescriptions for antibiotic use, antibiotic stewardship programs, educational programs targeting patients and healthcare providers, and limiting antibiotic use in agriculture, aquaculture, and animal husbandry. Early warning of the emergence and spread of antibiotic resistant bacteria would aid these efforts. The SARS-CoV-2 pandemic demonstrated the value of wastewater surveillance as an early warning system for viral spread and detection of the emergence of new viral strains. In this commentary we explore whether monitoring wastewater for antibiotic resistant genes and/or bacteria resistant to antibiotics might provide similarly useful information for public health action. Using carbapenem resistance as an example, we highlight technical challenges associated with using wastewater to quantify temporal/spatial trends in antibiotic resistant bacteria (ARBs) and antibiotic resistant genes (ARGs) and compare with clinical information. We also comment on using wastewater to track foodborne outbreaks. We conclude with our assessment that beyond source tracking the value added of screening wastewater for ARBs and ARGs for direct public health action is relatively low with current technologies compared to surveillance methods already in place.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Michigan Department of Health & Human Services through the Michigan Sequencing Academic Partnership for Public Health Innovation and Response (MI-SAPPHIRE) grant (S MA-2022 (ELCEDE-UM) 10/01/2021 to 07/31/2024, (BF mPI), and the wastewater surveillance program (SEWER network grant, KRW and MCE coPIs). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The used only openly available human data that were originally located at https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/HAI-SHARP/CRE/CP-CRE-Surveillance-Report-2018-2022-Final.pdf?rev=b5ee21278e6c4c1c91e7ce116bf25403&hash=5AE501DE9961C2B742D69CD5CA453B16 (Accessed February 28, 2024)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
